379 related articles for article (PubMed ID: 23153559)
21. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
22. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
23. Comparison of hepatocarcinogen-induced gene expression profiles in conventional primary rat hepatocytes with in vivo rat liver.
Doktorova TY; Ellinger-Ziegelbauer H; Vinken M; Vanhaecke T; van Delft J; Kleinjans J; Ahr HJ; Rogiers V
Arch Toxicol; 2012 Sep; 86(9):1399-411. PubMed ID: 22484513
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
Osimitz TG; Droege W; Boobis AR; Lake BG
Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of hormonal carcinogenesis in the p53+/- hemizygous knockout mouse: studies with diethylstilbestrol.
Carmichael PL; Mills JJ; Campbell M; Basu M; Caldwell J
Toxicol Pathol; 2001; 29 Suppl():155-60. PubMed ID: 11695552
[TBL] [Abstract][Full Text] [Related]
26. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene.
Ide F; Kitada M; Sakashita H; Kusama K; Tanaka K; Ishikawa T
Am J Pathol; 2003 Nov; 163(5):1729-33. PubMed ID: 14578172
[TBL] [Abstract][Full Text] [Related]
27. Failure of the standard battery of short-term tests in detecting some rodent and human genotoxic carcinogens.
Brambilla G; Martelli A
Toxicology; 2004 Mar; 196(1-2):1-19. PubMed ID: 15036752
[TBL] [Abstract][Full Text] [Related]
28. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice.
Rebel H; Kram N; Westerman A; Banus S; van Kranen HJ; de Gruijl FR
Carcinogenesis; 2005 Dec; 26(12):2123-30. PubMed ID: 16051635
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the in vivo genotoxic potential of three carcinogenic aromatic amines using the Big Blue transgenic mouse mutation assay.
Suter W; Ahiabor R; Blanco B; Locher F; Mantovani F; Robinson M; Sreenan G; Staedtler F; Swingler T; Vignutelli A; Perentes E
Environ Mol Mutagen; 1996; 28(4):354-62. PubMed ID: 8991064
[TBL] [Abstract][Full Text] [Related]
30. Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.
Recio L; Everitt J
Comp Med; 2001 Oct; 51(5):399-405. PubMed ID: 11924798
[TBL] [Abstract][Full Text] [Related]
31. A feasibility study: Can information collected to classify for mutagenicity be informative in predicting carcinogenicity?
Petkov PI; Patlewicz G; Schultz TW; Honma M; Todorov M; Kotov S; Dimitrov SD; Donner EM; Mekenyan OG
Regul Toxicol Pharmacol; 2015 Jun; 72(1):17-25. PubMed ID: 25792138
[TBL] [Abstract][Full Text] [Related]
32. Effect of p53 haploinsufficiency on melphalan-induced genotoxic effects in mouse bone marrow and peripheral blood.
Ranaldi R; Palma S; Tanzarella C; Lascialfari A; Cinelli S; Pacchierotti F
Mutat Res; 2007 Feb; 615(1-2):57-65. PubMed ID: 17109898
[TBL] [Abstract][Full Text] [Related]
33. Effects of p53 knockout on ochratoxin A-induced genotoxicity in p53-deficient gpt delta mice.
Hibi D; Kijima A; Suzuki Y; Ishii Y; Jin M; Sugita-Konishi Y; Yanai T; Nishikawa A; Umemura T
Toxicology; 2013 Feb; 304():92-9. PubMed ID: 23261758
[TBL] [Abstract][Full Text] [Related]
34. Carcinogen-induced inflammation and immunosuppression are enhanced in xeroderma pigmentosum group A model mice associated with hyperproduction of prostaglandin E2.
Miyauchi-Hashimoto H; Kuwamoto K; Urade Y; Tanaka K; Horio T
J Immunol; 2001 May; 166(9):5782-91. PubMed ID: 11313422
[TBL] [Abstract][Full Text] [Related]
35. Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?
Doktorova TY; Pauwels M; Vinken M; Vanhaecke T; Rogiers V
Crit Rev Toxicol; 2012 Feb; 42(2):91-106. PubMed ID: 22141324
[TBL] [Abstract][Full Text] [Related]
36. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet?
Benigni R
Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):407-17. PubMed ID: 22360376
[TBL] [Abstract][Full Text] [Related]
37. [Genotoxicity of carcinogenic substances in humans and animals].
Malaveille C; Bartsch H
J Toxicol Clin Exp; 1989; 9(2 Pt 2):15-25. PubMed ID: 2677321
[TBL] [Abstract][Full Text] [Related]
38. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
[TBL] [Abstract][Full Text] [Related]
39. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
40. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
